Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to participate in the following investor conferences:

• Guggenheim Oncology Conference 2023, New York CityFebruary 9, 2023, 10:45 am ESTWebcast

• SVB Securities Global Biopharma Conference, virtualFebruary 14, 2023, 5:00 pm ESTWebcast

• Citi's 2023 Oncology Leadership Summit, virtualFebruary 22, 2023, 2:00 pm ESTWebcast to be made available on Events page

For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.

About Caribou’s Novel Next-Generation CRISPR PlatformCRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences Contacts:

Investors:Amy Figueroa, CFA[email protected]

Media:Peggy Vorwald, Ph.D.[email protected]

Investors and Media:Elizabeth Wolffe, Ph.D., and Sylvia WheelerWheelhouse LSA[email protected][email protected]

Source: Caribou Biosciences, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Orion to Present at the 28th Annual H.C. Wainwright Global Investment Conference
• Longtime AIM Mail Center in Cypress, CA Transitions to New Ownership After More Than 30 Years of Service
• Genesis Innovation Group Appoints Patrick Jamnik as Chief of Staff